Topic summary

Why cagrilintide alone is discussed so much less than in combination

Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema Solved Closed

This is a generated summary. It shows the 9 most-liked posts from a topic of 109, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

k.brandl_deTL3Translator · DE Solution21 Mar 2025#5

On the opening post — agreed on the reasoning, with one qualification.

Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.

6 likes 16mo

d.bramleyTL3Regular21 Mar 2025#7

m.eriksen, post #1: Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Session topic: SURMOUNT-OSA ( N Engl J Med , 2024). Please read it before posting; the discussion is much better when everyone has. The question I would like us to start with is… Go to post

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

30 likes in reply to #1 16mo

slow_titratorTL2Regular24 Mar 2025#22

r.mensah, post #16: Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled. Go to post

post #21 is right about the mechanism and I think understates the practical bit.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

30 likes in reply to #16 16mo

l.ferreiraTL2 Moderator26 Mar 2025#34

j.falk, post #23: Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound. Go to post

Is synergy the right word for the combination data? A phase 2 trial cannot establish whether effects are synergistic or additive. Synergy is a mechanistic claim that requires a designed experiment to support it. The combination works, but the mechanism is unsettled.

32 likes in reply to #23 16mo

t.dumitruTL2 Moderator28 Mar 2025#50

n.vukovic, post #2: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

32 likes in reply to #2 16mo

DSakamotoTL3Regular29 Mar 2025#58

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

28 likes 16mo

s.poulsenTL3Regular30 Mar 2025#62

k.brandl_de, post #5: On the opening post — agreed on the reasoning, with one qualification. Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive. Go to post

post #61 answers the question as asked. The question underneath it is different.

28 likes in reply to #5 16mo

g.ekstromTL2 Moderator30 Mar 2025 · edited#69

d.bramley, post #7: Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection. Go to post

29 likes in reply to #7 16mo

isotonic_sheetTL3Regular31 Mar 2025#74

n.moreau, post #41: Coming back to post #39, because the follow-up matters more than the original answer. Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier. Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

30 likes in reply to #41 16mo

Read the full topic (109 posts)

This topic was closed 90 days after the last reply. Closing is automatic for quiet topics so that a settled answer does not collect new questions underneath it. If you have a follow-up, open a new topic and link back to this one — that keeps both readable and gives your question its own title.

Suggested topics

Topic	Participants	Replies	Views	Activity
Amylin analogue mechanism: satiety signalling separate from GLP-1 Compounds › Cagrilintide & amylin analogues effect size randomised trial cagrilintide cagrisema Solved Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SCALE ( N Engl J Med , 2015) and…	+128	142	38k	13mo
Second pass at: Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues amylin analogues effect size cagrilintide cagrisema Closed Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…	+15	19	22k	18mo
Reading a combination trial: attributing effect to components Compounds › Cagrilintide & amylin analogues cagrisema amylin analogues effect size cagrilintide Closed On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…		4	19k	11mo
Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema effect size Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of a…	+29	36	31k	1d
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+88	93	29k	11mo

Related topics — sharing the tags effect size, amylin analogues, cagrisema

Topic	Participants	Replies	Views	Activity
Comparing tirzepatide and semaglutide is harder than the tables suggest Compounds › Tirzepatide SURMOUNT programme randomised trial effect size Posting this under the heading it deserves: Comparing tirzepatide and semaglutide is harder than the tables suggest Everything below is what sits behind that. Comparing SCALE ( N Engl J Med , 2015) with STEP…		2	3.8k	10mo
What a confidence interval means, from scratch — the long version Research Methods › Statistics effect size worked example confounding number needed to treat The question in the title: What a confidence interval means, from scratch — the long version I will give what I have already checked below so nobody repeats it. I have seen SURMOUNT-2 ( Lancet , 2023) cited…	+16	20	2.3k	8mo
A 40-week log with the measurement method stated — does this still hold? Outcomes › Progress reports effect size DXA data table Solved A 40-week log with the measurement method stated — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. Longitudinal report with the method stated,…	+1	5	14k	2mo
Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Compounds › Semaglutide semaglutide effect size STEP programme randomised trial Solved Revisiting: What SELECT changed about how semaglutide is discussed, and what it did not Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J…		2	1.9k	5mo
[2026 update] Journal club: what we got wrong in an earlier session Evidence › Journal club journal club effect size estimand number needed to treat Solved Journal club: what we got wrong in an earlier session — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+5	9	4.2k	1d